Additional file 2 of Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial

Authors :: Lieverse, Relinde I. Y.
Limbergen, Evert J. Van
Oberije, Cary J. G.
Troost, Esther G. C.
Hadrup, Sine R.
Dingemans, Anne-Marie C.
Lizza E. L. Hendriks
Eckert, Franziska
Hiley, Crispin
Dooms, Christophe
Lievens, Yolande
Jong, Monique C. De
Bussink, Johan
Geets, Xavier
Valentini, Vincenzo
Elia, Giuliano
Neri, Dario
Billiet, Charlotte
Abdollahi, Amir
Pasquier, David
Boisselier, Pierre
Yaromina, Ala
Ruysscher, Dirk De
Dubois, Ludwig J.
Lambin, Philippe
Publisher :: figshare
Abstract: Additional file 2: Supplementary Table 2. The informed consent form used for ImmunoSABR phase 2 trial.

Tools